

Hideaki Miyoshi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5224128/publications.pdf>

Version: 2024-02-01

88
papers

2,368
citations

361413

20
h-index

214800

47
g-index

88
all docs

88
docs citations

88
times ranked

3996
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of lipid droplets in metabolic disease in rodents and humans. <i>Journal of Clinical Investigation</i> , 2011, 121, 2102-2110.	8.2	526
2	Perilipin Promotes Hormone-sensitive Lipase-mediated Adipocyte Lipolysis via Phosphorylation-dependent and -independent Mechanisms. <i>Journal of Biological Chemistry</i> , 2006, 281, 15837-15844.	3.4	259
3	Control of Adipose Triglyceride Lipase Action by Serine 517 of Perilipin A Globally Regulates Protein Kinase A-stimulated Lipolysis in Adipocytes. <i>Journal of Biological Chemistry</i> , 2007, 282, 996-1002.	3.4	252
4	Adipose triglyceride lipase regulates basal lipolysis and lipid droplet size in adipocytes. <i>Journal of Cellular Biochemistry</i> , 2008, 105, 1430-1436.	2.6	138
5	The Phenotype of Infiltrating Macrophages Influences Arteriosclerotic Plaque Vulnerability in the Carotid Artery. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2013, 22, 910-918.	1.6	126
6	HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1201-1204.	0.7	94
7	Perilipin Overexpression in White Adipose Tissue Induces a Brown Fat-Like Phenotype. <i>PLoS ONE</i> , 2010, 5, e14006.	2.5	72
8	Perilipin overexpression in mice protects against diet-induced obesity. <i>Journal of Lipid Research</i> , 2010, 51, 975-982.	4.2	70
9	Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. <i>Endocrine Journal</i> , 2017, 64, 363-367.	1.6	70
10	Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. <i>Endocrine Journal</i> , 2016, 63, 589-596.	1.6	49
11	Dynamics of Lipid Droplet-Associated Proteins during Hormonally Stimulated Lipolysis in Engineered Adipocytes: Stabilization and Lipid Droplet Binding of Adipocyte Differentiation-Related Protein/Adipophilin. <i>Molecular Endocrinology</i> , 2006, 20, 459-466.	3.7	47
12	A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2). <i>PLoS ONE</i> , 2015, 10, e0135854.	2.5	40
13	A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 54.	2.7	35
14	A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1). <i>PLoS ONE</i> , 2016, 11, e0164255.	2.5	29
15	Tenofovir disoproxil fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2021, 56, 168-180.	5.1	29
16	Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. <i>Metabolism: Clinical and Experimental</i> , 2019, 98, 27-36.	3.4	28
17	Favorable effect of sodium glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1272-1277.	2.4	28
18	Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. <i>Journal of Diabetes Investigation</i> , 2019, 10, 699-705.	2.4	26

#	ARTICLE	IF	CITATIONS
19	The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). <i>Cardiovascular Diabetology</i> , 2017, 16, 125.	6.8	24
20	Serum adiponectin and insulin secretion: A direct or inverse association?. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1106-1109.	2.4	23
21	Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages. <i>Scientific Reports</i> , 2018, 8, 6864.	3.3	22
22	Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial. <i>Journal of Diabetes Investigation</i> , 2018, 9, 119-126.	2.4	21
23	Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing β^2 -Cell Mass in db/db Mice. <i>Diabetes</i> , 2021, 70, 917-931.	0.6	17
24	Protective effect of sodium-glucose cotransporter ² inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type ² diabetes. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1510-1517.	2.4	16
25	Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea. <i>Journal of Diabetes Investigation</i> , 2019, 10, 367-374.	2.4	15
26	Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation. <i>Endocrine Journal</i> , 2019, 66, 937-941.	1.6	15
27	Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001787.	2.8	15
28	Impact of Glucose Loading on Variations in CD4+ and CD8+ T Cells in Japanese Participants with or without Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2018, 9, 81.	3.5	14
29	Effect of switching from pioglitazone to the sodium glucose co-transporter ² inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 710-714.	4.4	12
30	Favourable effect of the sodium-glucose co-transporter ² inhibitor canagliflozin plus the dipeptidyl peptidase ⁴ inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 458-462.	4.4	12
31	Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus. <i>Endocrine Journal</i> , 2016, 63, 747-753.	1.6	11
32	Overexpression of perilipin1 protects against atheroma progression in apolipoprotein E knockout mice. <i>Atherosclerosis</i> , 2018, 269, 192-196.	0.8	11
33	The role of glucokinase and insulin receptor substrate-2 in the proliferation of pancreatic beta cells induced by short-term high-fat diet feeding in mice. <i>Metabolism: Clinical and Experimental</i> , 2018, 85, 48-58.	3.4	11
34	Case of fulminant type ¹ diabetes induced by the anti-programmed death ¹ ligand ¹ antibody, avelumab. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1385-1387.	2.4	10
35	Relationships between plasma lactate, plasma alanine, genetic variations in lactate transporters and type 2 diabetes in the Japanese population. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, 131-138.	2.2	10
36	Impaired insulin secretion predicting unstable glycemic variability and time below range in type ² diabetes patients regardless of glycosylated hemoglobin or diabetes treatment. <i>Journal of Diabetes Investigation</i> , 2021, 12, 738-746.	2.4	10

#	ARTICLE	IF	CITATIONS
37	Proinsulin is sensitive to reflect glucose intolerance. <i>Journal of Diabetes Investigation</i> , 2020, 11, 75-79.	2.4	8
38	Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 4.	2.7	8
39	Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes. <i>Journal of Diabetes Investigation</i> , 2021, 12, 176-183.	2.4	8
40	Effects of 50 mg vildagliptin twice daily <i>vs.</i> 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose. <i>Endocrine Journal</i> , 2017, 64, 417-424.	1.6	7
41	Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes—Randomized controlled study. <i>Endocrine Journal</i> , 2018, 65, 141-150.	1.6	7
42	Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2019, 10, 429-438.	2.4	7
43	The Association of Cardio-Ankle Vascular Index and Ankle-Brachial Index with Macroangiopathy in Patients with Type 2 Diabetes Mellitus. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 616-623.	2.0	7
44	Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring. <i>Scientific Reports</i> , 2021, 11, 9057.	3.3	7
45	Close association between non-alcoholic fatty liver disease and ossification of the posterior longitudinal ligament of the spine. <i>Scientific Reports</i> , 2021, 11, 17412.	3.3	7
46	Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin. <i>Endocrine Journal</i> , 2019, 66, 995-1000.	1.6	6
47	Effects of <i>Palmaria palmata</i> on lipid metabolism and glycemic control in participants with hypercholesterolemia in a randomized double-blind placebo-controlled trial. <i>Phytotherapy Research</i> , 2020, 34, 2303-2312.	5.8	6
48	Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia. <i>Journal of Diabetes Investigation</i> , 2021, 12, 651-657.	2.4	6
49	Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 532.	4.7	6
50	Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in <i>db/db</i> mice. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 391-401.	4.4	6
51	Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor. <i>Medicine (United States)</i> , 2021, 100, e27895.	1.0	6
52	Lipid Droplet Protein PLIN1 Regulates Inflammatory Polarity in Human Macrophages and is Involved in Atherosclerotic Plaque Development by Promoting Stable Lipid Storage. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 170-181.	2.0	6
53	Dipeptidyl peptidase 4 inhibitor might exacerbate Graves' disease: A multicenter observational case-control study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1978-1982.	2.4	5
54	Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-9.	2.3	5

#	ARTICLE	IF	CITATIONS
55	Insulin-Induced Distant Site Lipoatrophy. <i>Diabetes Care</i> , 2017, 40, e67-e68.	8.6	4
56	Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment. <i>Frontiers in Endocrinology</i> , 2019, 10, 131.	3.5	4
57	Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study. <i>Journal of Diabetes Investigation</i> , 2020, 11, 964-970.	2.4	4
58	Silent pituitary adenoma and metabolic disorders: obesity, abnormal glucose tolerance, hypertension and dyslipidemia. <i>Endocrine Journal</i> , 2021, 68, 195-200.	1.6	4
59	The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 37.	2.7	4
60	Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseoglitazone in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 109069.	2.8	4
61	Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis. <i>Journal of Diabetes Investigation</i> , 2020, 12, 1293-1300.	2.4	3
62	Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The Tj ETQq0 0 0 rgBT7 Overlock 3 10 Tf 50 4).	2.5	3
63	Glucokinase is required for high-starch diet-induced β -cell mass expansion in mice. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1545-1554.	2.4	3
64	Impact of low-starch high-fiber pasta on postprandial blood glucose. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 487-493.	2.6	3
65	Citelman's syndrome with hyperphosphatemia, effectively responding to single oral magnesium oxide administration. <i>Medicine (United States)</i> , 2019, 98, e16408.	1.0	2
66	Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseoglitazone on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study. <i>BMJ Open</i> , 2020, 10, e034883.	1.9	2
67	Inverse correlation between serum high-molecular-weight adiponectin and proinsulin level in a Japanese population: The Dynamics of Lifestyle and Neighborhood Community on Health Study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 63-66.	2.4	2
68	The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 37, 100376.	2.2	2
69	Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1417-1424.	2.4	2
70	A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2021, 12, 1341-1357.	2.5	2
71	Severe infection including disseminated herpes zoster triggered by subclinical Cushing's disease: a case report. <i>BMC Endocrine Disorders</i> , 2021, 21, 84.	2.2	2
72	Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?. <i>Endocrine Journal</i> , 2022, 69, 495-509.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis. Pituitary, 2022, 25, 321.	2.9	2
74	Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study). BMJ Open, 2022, 12, e056885.	1.9	2
75	Evaluation of thrice-daily injections of insulin Lispro Mix 50/50 versus basal-bolus therapy in perioperative patients with type 2 diabetes. Diabetology International, 2014, 5, 117-121.	1.4	1
76	Potential Importance of a Histopathological Analysis in Thyroidal Diseases with High Serum IgG4 Levels. Internal Medicine, 2018, 57, 453-453.	0.7	1
77	The data of change in macrophage gene expression which induced by perilipin 1 overexpression. Data in Brief, 2018, 19, 179-182.	1.0	1
78	Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin. Journal of Diabetes Investigation, 2021, 12, 1395-1399.	2.4	1
79	Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor. Internal Medicine, 2021, 60, 2375-2383.	0.7	1
80	A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg. Journal of Diabetes Investigation, 2022, , .	2.4	1
81	Direct visualization of glucagon-like peptide-1 secretion by fluorescent fusion proteins. Journal of Diabetes Investigation, 2022, 13, 1134-1139.	2.4	1
82	Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report. Journal of the Endocrine Society, 2021, 5, A194-A194.	0.2	0
83	False hypercortisolemia due to abnormal albumin-cortisol binding in a patient with familial dysalbuminemic hyperthyroxinemia. Thyroid, 2021, , .	4.5	0
84	Comment on "Elevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Report". Annals of Thoracic and Cardiovascular Surgery, 2018, 24, 165-166.	0.8	0
85	MON-483 Familial Dysalbuminemic Hyperthyroxinemia with False Hypercortisolemia. Journal of the Endocrine Society, 2020, 4, .	0.2	0
86	SAT-271 Block and Replace Therapy Successfully Improved Symptoms in Recurrent Cyclic Cushing's Disease. Journal of the Endocrine Society, 2020, 4, .	0.2	0
87	SAT-282 Hypothalamic Pituitary Adrenal Axis Hyperactivity in Db/db Mice. Journal of the Endocrine Society, 2020, 4, .	0.2	0
88	The agreement between measured HbA1c and optimized target HbA1c based on the Dementia Assessment Sheet for Community-based Integrated Care System 8 items (<sc>DASC</sc>): A cross-sectional study of elderly patients with diabetes. Geriatrics and Gerontology International, 2022, 22, 560-567.	1.5	0